Brought to you by 
Polaris, Arch provide $15mm Series A financing to deCODE spin-off NextCODE Health
14 Jan 2015
Executive Summary
NextCODE Health LLC, a firm focused on diagnosing genetic diseases, launched with $15mm in Series A funding from Polaris Partners and Arch Venture Partners. The start-up, a spin-off of Icelandic company deCODE genetics EHF (a division of Amgen Inc.), is beginning operations with an exclusive five-year license to deCODE’s technology related to sequence-based clinical diagnostics. NextCODE will use the new money to scale the integration of its genomics services into clinical markets.
Deal Industry
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Polaris, Arch provide $15mm Series A financing to deCODE spin-off NextCODE Health
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice